Literature DB >> 20041351

Management of recurrent rectal cancer.

Philippe Bouchard1, Jonathan Efron.   

Abstract

BACKGROUND: Here we present a concise review on the evaluation and management of locally recurrent rectal cancer, which despite marked reductions in the rate of recurrent rectal cancer remains an important problem.
METHODS: This educational review discusses the diagnosis, evaluation, and management of recurrent rectal cancer.
RESULTS: Despite improvements in both the neoadjuvant and surgical management of rectal cancer, local recurrence is still an important problem, with documented recurrence rates of 4% to 8%. The local management of recurrence requires a team of specialist. Accurate detection and diagnosis followed by chemoradiotherapy and surgical resection may result in 5-year survival rates of up to 35%.
CONCLUSIONS: We discuss the diagnosis, evaluation, and management of locally recurrent rectal cancer. Locally recurrent rectal cancer can be successfully managed with multimodal therapy leading to successful palliation and often cure.

Entities:  

Mesh:

Year:  2009        PMID: 20041351     DOI: 10.1245/s10434-009-0861-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  27 in total

1.  Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease.

Authors:  Amar U Kishan; Justin C Voog; Jonathan Wiseman; Ryan R Cook; Marek Ancukiewicz; Percy Lee; David P Ryan; Jeffrey W Clark; David L Berger; James C Cusack; Jennifer Y Wo; Theodore S Hong
Journal:  Br J Radiol       Date:  2017-06-14       Impact factor: 3.039

2.  Rectal cancer : when is the local recurrence risk low enough to refrain from the aim to prevent it?

Authors:  M L Sautter-Bihl; W Hohenberger; R Fietkau; C Rödel; H Schmidberger; R Sauer
Journal:  Strahlenther Onkol       Date:  2013-02       Impact factor: 3.621

Review 3.  Surgery for Locally Advanced T4 Rectal Cancer: Strategies and Techniques.

Authors:  Ramzi M Helewa; Jason Park
Journal:  Clin Colon Rectal Surg       Date:  2016-06

4.  Salvage high-dose-rate interstitial brachytherapy for locally recurrent rectal cancer.

Authors:  Antônio Cássio Assis Pellizzon
Journal:  Radiol Bras       Date:  2016 May-Jun

Review 5.  Locally Advanced Disease and Pelvic Exenterations.

Authors:  Christos Kontovounisios; Paris Tekkis
Journal:  Clin Colon Rectal Surg       Date:  2017-12-01

6.  Intensity-modulated radiation therapy for pelvic oligo-recurrence from rectal cancer: long-term results from a single institution.

Authors:  Xiang-Gao Zhu; Yong-Heng Li; Xiao-Fan Li; Yong Cai
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 7.  Management of stage IV rectal cancer: palliative options.

Authors:  Sean M Ronnekleiv-Kelly; Gregory D Kennedy
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

8.  Postoperative complications following intraoperative radiotherapy in abdominopelvic malignancy: A single institution analysis of 113 consecutive patients.

Authors:  Eihab Abdelfatah; Andrew Page; Justin Sacks; Phillip Pierorazio; Trinity Bivalacqua; Jonathan Efron; Stephanie Terezakis; Susan Gearhart; Sandy Fang; Bashar Safar; Timothy M Pawlik; Elwood Armour; Amy Hacker-Prietz; Joseph Herman; Nita Ahuja
Journal:  J Surg Oncol       Date:  2017-03-02       Impact factor: 3.454

9.  Outcomes of pelvic exenteration for recurrent or primary locally advanced colorectal cancer.

Authors:  Hwa Yeon Yang; Sung Chan Park; Jong Hee Hyun; Ho Kyung Seo; Jae Hwan Oh
Journal:  Ann Surg Treat Res       Date:  2015-08-24       Impact factor: 1.859

10.  Salvage high-dose-rate interstitial brachytherapy for locally recurrent rectal cancer: long-term follow-up results.

Authors:  Masahiro Morimoto; Fumiaki Isohashi; Yasuo Yoshioka; Osamu Suzuki; Yuji Seo; Toshiyuki Ogata; Yuichi Akino; Masahiko Koizumi; Kazuhiko Ogawa
Journal:  Int J Clin Oncol       Date:  2013-06-01       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.